A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects
Inclusion Criteria:
* Medically healthy based on medical records and study specific assessments
Exclusion Criteria:
* Presence or history of severe adverse reaction to any drug or drug excipient